公开(公告)号：US20170121346A1

公开(公告)日：2017-05-04

申请号：US15337184

申请日：2016-10-28

Applicant: eFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E. Webber ,  Mike Shaghafi ,  Douglas Murphy ,  Chinh Tran

IPC: C07D498/04 ,  C07D403/12 ,  C07D239/42 ,  C07D403/14 ,  C07D409/12 ,  C07D239/48 ,  C07D409/14 ,  C07D487/04 ,  C07D471/04 ,  C07D471/10 ,  C07D491/107 ,  C07D401/12 ,  C07D473/34 ,  C07D417/12

CPC classification number: C07D498/04 ,  C07D239/42 ,  C07D239/48 ,  C07D239/49 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/10 ,  C07D473/34 ,  C07D487/04 ,  C07D491/107

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US20190152988A1

公开(公告)日：2019-05-23

申请号：US16171606

申请日：2018-10-26

Applicant: eFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E. Webber ,  Mike Shaghafi ,  Douglas Murphy ,  Chinh Tran

IPC: C07D498/04 ,  C07D487/04 ,  C07D417/12 ,  C07D409/12 ,  C07D239/49 ,  C07D239/42 ,  C07D403/14 ,  C07D491/107 ,  C07D403/12 ,  C07D239/48 ,  C07D409/14 ,  C07D471/04 ,  C07D471/10 ,  C07D473/34 ,  C07D401/12

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US11286268B1

公开(公告)日：2022-03-29

申请号：US16916820

申请日：2020-06-30

Applicant: EFFECTOR THERAPEUTICS, INC.

Inventor： Samuel Sperry ,  Alan X. Xiang ,  Justin T. Ernst ,  Siegfried H. Reich ,  Paul A. Sprengeler ,  Mike Shaghafi ,  Theo Michels ,  Christian Nilewski ,  Chinh Viet Tran ,  Garrick Kenneth Packard ,  Alan Grubbs ,  Kaveri Urkalan ,  Takasuke Mukaiyama

IPC: C07D519/00 ,  C07D495/04

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

公开(公告)号：US10112955B2

公开(公告)日：2018-10-30

申请号：US15337184

申请日：2016-10-28

Applicant: eFFECTOR THERAPEUTICS, INC.

Inventor： Paul A. Sprengeler ,  Siegfried H. Reich ,  Justin T. Ernst ,  Stephen E. Webber ,  Mike Shaghafi ,  Douglas Murphy ,  Chinh Tran

IPC: C07D498/04 ,  C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D239/42 ,  C07D239/49 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04 ,  C07D239/48 ,  C07D409/14 ,  C07D471/04 ,  C07D471/10 ,  C07D473/34 ,  C07D491/107

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.